Kelly Steven 4
4 · Carisma Therapeutics Inc. · Filed Jun 8, 2023
Insider Transaction Report
Form 4
Kelly Steven
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2023-06-06+600,000→ 600,000 totalExercise: $7.25Exp: 2033-06-06→ Common Stock (600,000 underlying)
Footnotes (1)
- [F1]The shares underlying this option vest over four years, with 25% of the shares vesting on June 6, 2024 and the remaining shares vesting over the next three years thereafter in equal monthly installments, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date.